Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase II Study on Safety and Efficacy of Fludarabine Plus Treosulfan (14g) (FT14) Conditioning Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Acute Myeloid Leukemia (AML) Patients (≥40 <65years) (FT14-Trial)

NCT07232953 is registered in ClinicalTrials.gov with Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia as lead sponsor.

NCT NCT07232953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07232953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase II Study on Safety and Efficacy of Fludarabine Plus Treosulfan (14g) (FT14) Conditioning Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Acute Myeloid Leukemia (AML) Patients (≥40 <65years) (FT14-Trial)
Lead sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 10, 2022
Completion date
June 30, 2027
Enrollment
82 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia (aml), hematopoietic stem cell transplant (hsct)